

Information For the User
Moxifloxacin (400mg) + Cefixime (400mg)

Moxolunic CF SR Tablet

Moxolunic CF SR Tablet

Composition (Each film-coated sustained-release tablet contains):

- **Moxifloxacin Hydrochloride** eq. to Moxifloxacin – 400 mg
- **Cefixime Trihydrate** eq. to Cefixime – 400 mg
- Excipients – q.s.

Dosage Form:

- Sustained-Release Tablet

Description:

Moxolunic CF SR Tablet is a fixed-dose combination of a fluoroquinolone (Moxifloxacin) and a third-generation cephalosporin (Cefixime) used for the treatment of moderate to severe bacterial infections, particularly those involving respiratory and genitourinary tracts.

Pharmacological Action:

- **Moxifloxacin** is a broad-spectrum antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV.
- **Cefixime** acts by inhibiting bacterial cell wall synthesis, exhibiting strong activity against Gram-negative and Gram-positive bacteria.

Indications:

- Community-acquired pneumonia
- Acute exacerbation of chronic bronchitis
- Urinary tract infections
- Typhoid fever
- Respiratory tract infections of mixed origin

Dosage and Administration:

- As directed by the physician.
- Typically once daily due to sustained-release profile.

Contraindications:

- Hypersensitivity to cephalosporins, fluoroquinolones, or any component of the tablet
- History of tendon disorders related to fluoroquinolone use
- Use with caution in patients with renal impairment

Warnings and Precautions:

- Monitor for signs of hypersensitivity or allergic reactions

- Risk of QT interval prolongation; caution in patients with known cardiac history
- Avoid in pregnancy and lactation unless clearly necessary
- Not recommended in pediatric population

Adverse Effects:

- Nausea, vomiting, diarrhea
- Headache, dizziness
- Rash or skin reactions
- Rare: tendon rupture, Clostridium difficile-associated diarrhea

Storage:

- Store below 25°C
- Protect from moisture and direct sunlight
- Keep out of reach of children

Conclusion:

Moxolunic CF SR Tablet delivers a potent dual antibacterial action in a sustained-release formulation, ensuring improved patient compliance and effective treatment outcomes across a spectrum of resistant bacterial infections.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for